Kamada (NASDAQ:KMDA) Reaches New 12-Month High – Still a Buy?

Kamada Ltd. (NASDAQ:KMDA) shares reached a new 52-week high during trading on Monday . The stock traded as high as $8.50 and last traded at $8.72, with a volume of 1115207 shares changing hands. The stock had previously closed at $7.69.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Friday, January 10th.

Kamada Trading Down 2.8 %

The company has a market cap of $446.79 million, a price-to-earnings ratio of 27.79, a PEG ratio of 0.88 and a beta of 0.99. The company’s 50 day moving average price is $6.63 and its 200 day moving average price is $5.93.

Institutional Trading of Kamada

Several hedge funds have recently modified their holdings of KMDA. Plato Investment Management Ltd purchased a new position in Kamada in the third quarter valued at about $117,000. Public Employees Retirement System of Ohio acquired a new position in Kamada during the third quarter worth $77,000. Finally, JPMorgan Chase & Co. purchased a new stake in Kamada during the fourth quarter worth $67,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.